Barratt

BAM Capital Partners with Milhaus to Launch Nox, A New Era in Multifamily Living in Pittsburgh, PA

Retrieved on: 
Thursday, March 14, 2024
Partnership, Nox, Millhouse, Barratt, Commercial property

Founded on a commitment to integrity, innovation, and excellence, BAM Capital has established itself as a leader in the multifamily real estate sector .

Key Points: 
  • Founded on a commitment to integrity, innovation, and excellence, BAM Capital has established itself as a leader in the multifamily real estate sector .
  • Milhaus, a premier real estate development and management company, brings its expertise in creating high-quality, sustainable urban housing solutions.
  • Their partnership with BAM Capital in developing Nox underscores a shared vision for excellence and a commitment to positively impacting the communities they serve.
  • "BAM Capital remains highly selective and opportunistic in its ongoing endeavor to be the most trusted steward of investor capital," notes Ivan Barratt, Founder and CEO of BAM Capital.

BAM Capital's Review - CEO's Meeting With Chase Bank CEO Jamie Dimon Teaches Life-Long Leadership Lessons

Retrieved on: 
Monday, March 4, 2024
Knowledge, Culture, Growth, History, Chase Bank, Barratt

INDIANAPOLIS, March 4, 2024 /PRNewswire/ -- In a once-in-a-lifetime encounter, Ivan Barratt, CEO and Founder of BAM Capital , recently had the esteemed opportunity to meet Jamie Dimon , the CEO of Chase Bank.

Key Points: 
  • INDIANAPOLIS, March 4, 2024 /PRNewswire/ -- In a once-in-a-lifetime encounter, Ivan Barratt, CEO and Founder of BAM Capital , recently had the esteemed opportunity to meet Jamie Dimon , the CEO of Chase Bank.
  • Describing the meeting as akin to meeting an icon like Kobe Bryant, Barratt shared his invaluable takeaways and the profound impact of Dimon's wisdom on his approach to leadership and business strategy.
  • This simple yet effective strategy highlights the importance of organization at the highest levels of leadership.
  • This meeting has not only enriched Barratt's leadership perspective but also reinforced the principles guiding BAM Capital's approach to business and investment strategy.

NASA's SpaceX Crew-8 Launches to International Space Station

Retrieved on: 
Monday, March 4, 2024
Social media, Roscosmos, NASA, Astronaut, Exploration, Research, Multimedia, Barratt, SpaceX launch vehicles, EST, Rotation, Mission control center, Commercial Crew Program, Discovery, Moon, Harmony, UV, Radiation, JAXA, Orbit, ExPRESS Logistics Carrier, NASA TV, Artemis, Kennedy Space Center, SpaceX, Spacecraft, Endeavour, International Space Station, Loral, Television, Science, ESA, Leonardo (ISS module), Johnson Space Center, European Space Agency, Fluid mechanics, Communications satellite

WASHINGTON, March 4, 2024 /PRNewswire/ -- An international crew of four reached orbit following a successful launch to the International Space Station at 10:53 p.m. EST Sunday from Launch Complex 39A at NASA's Kennedy Space Center in Florida.

Key Points: 
  • WASHINGTON, March 4, 2024 /PRNewswire/ -- An international crew of four reached orbit following a successful launch to the International Space Station at 10:53 p.m. EST Sunday from Launch Complex 39A at NASA's Kennedy Space Center in Florida.
  • NASA's SpaceX Crew-8 mission is the agency's eighth commercial crew rotation mission with the company to the space station.
  • "Congratulations to NASA and SpaceX on another successful launch to the International Space Station!
  • NASA teams will monitor space station operations throughout the flight from the Mission Control Center at the agency's Johnson Space Center in Houston.

Ayar Labs Adds Silicon Industry Veterans to Accelerate Growth

Retrieved on: 
Thursday, January 11, 2024
Technology, Hardware, Semiconductor, Other Technology, Computer science and engineering, Silicon, Intuition, Intel, MaxLinear, PCI Express, Associate, Intuitive Surgical, Professor, Multimedia, IonQ, AI, Microchip Technology, University, Ecosystem, Growth, MIT, IPO, TBPS, Electrical engineering, Rogers Corporation, Machine learning, Barratt, Ayar, Barefoot Networks, FPGA, Computer science, Management

Ayar Labs , a leader in silicon photonics for chip-to-chip connectivity, today announced two additions to its Board of Directors.

Key Points: 
  • Ayar Labs , a leader in silicon photonics for chip-to-chip connectivity, today announced two additions to its Board of Directors.
  • “The work Ayar Labs is doing to make optical I/O a reality is essential to the forward progress of the entire industry.
  • I look forward to helping Ayar Labs expand its reach across the ecosystem as the company moves into its next phase of growth,” said Moorthy.
  • Ayar Labs’ leadership in breakthrough optical I/O solutions enables system performance that is not possible with alternative approaches,” said Barratt.

Alpine Immune Sciences Presents Initial Clinical Data on Povetacicept in Autoimmune Glomerulonephritis in a Late-Breaking Poster Session at the American Society of Nephrology Kidney Week 2023

Retrieved on: 
Thursday, November 2, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, University of Leicester, Survival, FRCP, ALPN, GN, EGFR, Biomarker, Fig, Nephrology, PMN, MD, Inflammation, Cytokine, Doctor of Philosophy, Glomerular filtration rate, Immunoglobulin A, American Society of Nephrology, Multimedia, Society, BAFF, Glossary of education terms (G–L), Disease, Barratt, ASN, Webcast, Emory University School of Medicine, University, Immunoglobulin G, Autoimmunity, Glomerulonephritis, Patient, Infection, Vaccine, Sewage treatment, Pharmaceutical industry, Research, IgA nephropathy, Proteinuria, Alpine, Medicine, UPCR

RUBY-3 is a multiple ascending dose, multi-cohort, open label, phase 1b/2a study of povetacicept in autoimmune glomerulonephritis, where povetacicept is administered subcutaneously (SC) once every four weeks for up to 48 weeks.

Key Points: 
  • RUBY-3 is a multiple ascending dose, multi-cohort, open label, phase 1b/2a study of povetacicept in autoimmune glomerulonephritis, where povetacicept is administered subcutaneously (SC) once every four weeks for up to 48 weeks.
  • A higher dose of povetacicept, 240 mg SC every four weeks, continues to enroll, with initial data expected in 1H 2024.
  • A higher dose of povetacicept 240 mg every four weeks is currently being explored and will be of great interest.
  • “We eagerly await the initial data from the next 240 mg dose level in the first half of 2024.

MX Names Jane Barratt Chief Advocacy Officer and Head of Global Public Policy

Retrieved on: 
Wednesday, October 18, 2023
Fintech, Learning, Public policy, MX, Human, LEHI, Barratt, Growth, Ecosystem, CFPB, Dodd–Frank Wall Street Reform and Consumer Protection Act

LEHI, Utah, Oct. 18, 2023 /PRNewswire/ -- MX Technologies, Inc., an industry leader in Open Finance, today announced it has named Jane Barratt as its Chief Advocacy Officer and Head of Global Public Policy. She brings more than 25 years of experience working with financial institutions, technology and Fortune 500 companies, policymakers, and regulators, to drive business growth, increase the pace of innovation, and improve financial outcomes. Barratt will oversee the company's advocacy and global public policy efforts reporting to MX Chief Executive Officer Jim Magats.

Key Points: 
  • A leading voice in financial services, Barratt will lead the company's advocacy, government relations, and public policy efforts, advocating for a strong open finance ecosystem and improved financial outcomes for people and the businesses that serve them
    LEHI, Utah, Oct. 18, 2023 /PRNewswire/ -- MX Technologies, Inc., an industry leader in Open Finance, today announced it has named Jane Barratt as its Chief Advocacy Officer and Head of Global Public Policy.
  • Barratt will oversee the company's advocacy and global public policy efforts reporting to MX Chief Executive Officer Jim Magats.
  • Jane Barratt is a leading voice in the industry and long-time advocate for harnessing the power of financial data.
  • Partnering with customers, industry groups, policymakers, and regulators is critical to ensure a competitive and innovative future for financial services," said Jane Barratt, Chief Advocacy Officer and Head of Global Public Policy, MX.

Vera Therapeutics to Present Three Posters at the American Society of Nephrology Kidney Week 2023 Annual Meeting

Retrieved on: 
Friday, October 13, 2023
FRCP, Barratt, Abstract, COVID, Nephrology, Society, University, Therapy, ASN, Tetanus, University of Leicester, Diphtheria, American Society of Nephrology, Serum, Patient, Infection, Pharmaceutical industry, IgA nephropathy

BRISBANE, Calif., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that three abstracts on the Company’s product candidate atacicept in immunoglobulin A nephropathy (IgAN) have been selected for poster presentations at the American Society of Nephrology (ASN) Kidney Week 2023, which is taking place November 2–5, 2023, in Philadelphia, PA.

Key Points: 
  • Additional analysis of week 36 data from Phase 2b ORIGIN study show atacicept 150mg reduces serum Gd-IgA1, supporting atacicept’s potential as long-term disease-modifying IgAN therapy
    Atacicept showed continued protective titers to diphtheria and tetanus and balanced COVID infections vs. placebo in IgAN
    BRISBANE, Calif., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that three abstracts on the Company’s product candidate atacicept in immunoglobulin A nephropathy (IgAN) have been selected for poster presentations at the American Society of Nephrology (ASN) Kidney Week 2023, which is taking place November 2–5, 2023, in Philadelphia, PA.
    Kidney Week Poster Presentation Details:
    Jonathan Barratt, Ph.D., FRCP, The Mayer Professor of Renal Medicine, University of Leicester, UK

Vera Therapeutics to Host Key Opinion Webinar on Targeting the Source of IgA Nephropathy (IgAN) Featuring Jonathan Barratt, Ph.D., FRCP

Retrieved on: 
Thursday, November 17, 2022
COVID-19, Degenerative disease, Diagnosis, ASN, American Society of Nephrology, BYU College of Life Sciences, Immunoglobulin A, FRCP, BK virus, Union, ESRD, Food, University, Autoantibody, Dialysis, Radar, Therapy, College, B-cell activating factor, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Virus, TACI, Clinical trial, Cytokine, Biomarker, Surrogate, Coagulation, Chronic kidney disease, Standard of care, University of Leicester, Lupus nephritis, Society, International, Security (finance), B cell, Barratt, Research, BK, Kidney failure, Polyomaviridae, KOL, Vera, Pharmaceutical industry, Vaccine, IgA nephropathy

BRISBANE, Calif., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that it will host a key opinion leader (KOL) webinar on IgA nephropathy (IgAN), a common cause of kidney failure. The webinar will be held on Monday, November 28, 2022 at 2:00pm ET.

Key Points: 
  • Recent data presented by Dr. Barratt at the American Society of Nephrology (ASN) Kidney Week 2022 showed atacicept reduced immune complex levels in patients with IgAN.
  • In addition, the Vera Therapeutics leadership team will provide an overview of the ongoing Phase 2b ORIGIN trial of atacicept in IgAN and the Companys pipeline.
  • If the data from the ORIGIN trial are supportive, Vera Therapeutics expects to initiate a pivotal Phase 3 clinical trial of atacicept in 2023.
  • Atacicept showed a dose-dependent effect on key biomarkers and clinical markers in a Phase 2a clinical study in patients with IgAN.

Vera Therapeutics to Present Final Phase 2 Results of MAU868 in Kidney Transplant Recipients with Reactivated BK Virus Infection and New Analysis of Phase 2a JANUS Trial of Atacicept in IgA Nephropathy at the American Society of Nephrology Kidney Week 202

Retrieved on: 
Monday, October 17, 2022
Securities and Exchange Commission (Philippines), BK virus, B-cell activating factor, Therapy, Polyomaviridae, BKV, IgA nephropathy, Cytokine, BK, Degenerative disease, Society, Barratt, Patient, FRCP, Standard of care, Pfizer, Security (finance), B cell, Nephrology, Lupus nephritis, University, Autoantibody, Virus, Private Securities Litigation Reform Act, Biomarker, Vera, Immunosuppression, Immunoglobulin A, TACI, Coagulation, COVID-19, University of Leicester, Vaccine

BK Virus is a polyoma virus that can be reactivated in settings of immunosuppression, such as in kidney transplant.

Key Points: 
  • BK Virus is a polyoma virus that can be reactivated in settings of immunosuppression, such as in kidney transplant.
  • It is a leading cause of kidney transplant loss and transplant-associated morbidity; there are currently no approved treatments for BKV.
  • Vera holds an exclusive worldwide license from Amplyx Pharmaceuticals, Inc., a wholly owned subsidiary of Pfizer Inc., for the development and commercialization of MAU868 in all indications.
  • Atacicept showed a dose-dependent effect on key biomarkers and clinical markers in a Phase 2a clinical study in patients with IgAN.

Calliditas Therapeutics Launches an Online Patient Platform

Retrieved on: 
Saturday, May 14, 2022
Autoantibody, Kidney bean, Nasdaq Stockholm, Disease, Immunoglobulin A, IgA nephropathy, Nasdaq, Chronic kidney disease, Environment, Barratt, Therapy, Kidney, Nationwide, Caregiver, Mortality, Gut, A, Diagnosis, American depositary receipt, CALT, GLOBE, Online gambling, Pharmaceutical industry, Welander

STOCKHOLM, Sweden, May 14, 2022 (GLOBE NEWSWIRE) -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (Calliditas) today announced the launch of IgAN Connect, a new online platform to provide resources to people living with IgA nephropathy, or IgAN, a chronic autoimmune disease.

Key Points: 
  • STOCKHOLM, Sweden, May 14, 2022 (GLOBE NEWSWIRE) -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (Calliditas) today announced the launch of IgAN Connect, a new online platform to provide resources to people living with IgA nephropathy, or IgAN, a chronic autoimmune disease.
  • Bonnie Schneider, Director and Co-Founder of the IgA Nephropathy Foundation of America commented, IgA nephropathy is a complicated disease that can leave individuals with many unanswered questions.
  • With the launch of IgAN Connect, I am grateful that individuals will have even more resources to embark on this journey.
  • Calliditas common shares are listed on Nasdaq Stockholm (ticker: CALTX) and its American Depositary Shares are listed on the Nasdaq Global Select Market (ticker: CALT).